Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(KU 57788; NU-7441; KU57788; NU7441; NU 7441)
KU-57788 Chemical Structure
|Product name: KU-57788|
|Cat. No.: HY-11006|
KU-57788(NU7441) is a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor with IC50 value of are 14 nM; 1700, 5000, >100000 and >100000 nM for mTOR, PI 3K, ATM and ATR respectively; also is a modest inhibitor of BRD4 and BRDT with IC50s of 1 and 3.5 uM respectively.
IC50 value: 14 nM (DNA-PK); 1/3.5 uM(BRD4/BRDT) 
Target: DNA-PK; BRD4/BRDT
in vitro: NU7441 increased the cytotoxicity of ionizing radiation and etoposide in SW620, LoVo, and V3-YAC cells but not in V3 cells, confirming that potentiation was due to DNA-PK inhibition. NU7441 substantially retarded the repair of ionizing radiation-induced and etoposide-induced DSB. NU7441 appreciably increased G(2)-M accumulation induced by ionizing radiation, etoposide, and doxorubicin in both SW620 and LoVo cells . NU7441 strongly inhibited DNA-PK in cell lines (IC(50) = 0.3 μM) but only weakly inhibited PI3 K (IC(50) = 7 μM). NU7441 caused doxorubicin- and IR-induced DNA DSBs (measured by γ-H2AX foci) to persist and also slightly decreased homologous recombination activity, as assessed by Rad51 foci . NU7441 is a modest inhibitor of BRD4 and BRDT (IC50 = 1 and 3.5 SM, respectively), which establishes a single hydrogen bond in the KAc site through the chromenone oxygen with Asn140 .
in vivo: In mice bearing SW620 xenografts, NU7441 concentrations in the tumor necessary for chemopotentiation in vitro were maintained for at least 4 hours at nontoxic doses. NU7441 increased etoposide-induced tumor growth delay 2-fold without exacerbating etoposide toxicity to unacceptable levels .
|M.Wt||413.49||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
10 mM in DMSO
|1 mg||5 mg||10 mg|
|1 mM||2.4184 mL||12.0922 mL||24.1844 mL|
|5 mM||0.4837 mL||2.4184 mL||4.8369 mL|
|10 mM||0.2418 mL||1.2092 mL||2.4184 mL|
. Leahy JJ, et al. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6083-7.
. Tavecchio M, et al. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Cancer Chemother Pharmacol. 2012 Jan;69(1):155-64.
4-hydroxytamoxifen (OHT), an active metabolite of tamoxifen, is a selective estrogen receptor modulator, is in wide clinical use for the treatment and prevention of breast cancer.
ARV-825 is a BRD4 inhibitor with DC50 (50% of maximum degradation) ＜1nM for Burkitt(acute)s lymphoma (BL) cell lines. Affinity to BD1 and BD2 of BRD4 by ARV-825 is 90 and 28 nM, respectively.
BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM, BI2536 shows 4- and 11-fold greater selectivity against Plk2 and Plk3; BI2536 also is a BRD4 inhibitor(IC50= 25 nM).
BI-7273 is a selective, and cell-permeable BRD9 BD inhibitor.
BI-9564 is a selective, and cell-permeable BRD9 BD inhibitor, with Kd of 5.9 nM for BRD9, and IC50 of > 100 (mu)M for BET family.
Brefeldin A is a fungal metabolite that disrupts the structure and function of the Golgi apparatus; induces the Golgi proteins to redistribute into the ER and blocks the secretion from the Golgi apparatus. Brefeldin A increases CRISPR/Cas9-mediated editing frequency.
Bromosporine is a broad spectrum inhibitor for bromodomains with IC50 of 0.41 (mu)M, 0.29 (mu)M, 0.122 (mu)M and 0.017 (mu)M for BRD2, BRD4, BRD9 and CECR2, respectively.
Compound 401 is a synthetic inhibitor of DNA-PK (IC50 = 0.28 (mu)M) that also targets mTOR but not PI3K.
CPI 203 is a novel potent, selective and cell permeable inhibitor of the bromodomain and extra terminal (BET) family protein BRD4 with an IC50 of ~37 nM (BRD4 (alpha)-screen assay).
CPI-360 is a potent, selectiveEZH2inhibitor with IC50 of 0.5 nM and 2.5 nM nM for wt EZH2 and Y641N EZH2, respectively.
Other Countries & RegionsSee Worldwide Distributors